Cytoplasm Replacement Therapy
Cytoplasm Replacement Therapy - Related Videos
09:34
Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
0 Views •
Cited by 10 •
2017
Age-related diseases are associated with multiple defects in components of the cytoplasm. Here, we present a protocol to prepare plasma membrane vesicles from bone marrow mesenchymal stem cells. This technique could potentially be used as a means of cytoplasm replacement therapy to ameliorate or even reverse age-associated phenotypes.
01:30
Continuous Renal Replacement Therapy
0 Views •
2025
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:16
Cytoplasm
0 Views •
2026
The cytoplasm consists of organelles and a framework of protein scaffolds called the cytoskeleton suspended in an aqueous solution, the cytosol. The cytosol is a rich broth of water, ions, salts, and various organic molecules.Protein Folding and MisfoldingThe cytoplasm is the location for several cellular processes, including protein synthesis and folding. The aqueous nature of the cytosol promotes protein folding such that the hydrophobic amino acid side chains are buried in the protein core...
01:26
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
0 Views •
2025
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
07:42
Activation of Apoptosis by Cytoplasmic Microinjection of Cytochrome c
0 Views •
Cited by 15 •
2011
In this protocol, we describe the direct cytoplasmic microinjection of cytochrome c protein into fibroblasts and primary sympathetic neurons. This technique allows for the introduction of cytochrome c protein into the cytoplasm of cells and mimics the release of cytochrome c from mitochondria, which occurs during apoptosis.
FAQs
The central mechanism is altering which mitochondria accompany the recipient cell’s nuclear material. Introducing donor cytoplasm with healthy mitochondria can reduce the proportion or transmission of pathogenic mitochondrial DNA in an oocyte or early embryo. This makes cytoplasmic composition biologically important even when the intervention is aimed at preventing inheritance rather than correcting nuclear genetic material.
Mitochondria and other cytoplasmic components participate in cellular signaling, including pathways involved in innate immunity. Changing that cellular environment may therefore affect how a cell responds to infectious stimuli or develops inflammation. Cytoplasm replacement therapy provides an experimental framework for examining these relationships, rather than establishing that the intervention universally improves infection resistance or inflammatory outcomes.
Spindle transfer and pronuclear transfer represent different procedural routes for introducing donor cytoplasm containing healthy mitochondria. Both are associated with mitochondrial replacement, but they act at different stages of the oocyte or early embryo process. Comparing them helps researchers study how the timing and handling of cytoplasmic material may influence the resulting cell or embryo.
Assessment must extend beyond the immediate introduction of donor cytoplasm. Researchers must consider whether pathogenic mitochondrial DNA transmission is reduced, whether cellular function is restored or supported, and whether cytoplasmic signaling remains appropriate. Technical performance, ethical acceptability, and long-term safety are also essential, because short-term cellular changes may not predict later biological consequences.
At a conceptual level, the workflow involves selecting an oocyte or early embryo, introducing cytoplasm from a donor source containing healthy mitochondria, and examining whether mitochondrial DNA transmission and cellular function are favorably affected. Spindle transfer and pronuclear transfer provide alternative procedural frameworks. Because the approach remains experimental, technical execution and long-term assessment are central parts of the process.
Its relevance comes from the connection between mitochondria, cytoplasmic signaling, and innate immune pathways. By changing cytoplasmic contents, researchers can investigate whether mitochondrial state influences susceptibility to infection or the strength of inflammatory responses. The approach therefore links emerging cell therapy research with questions about how intracellular organization shapes immune behavior, while retaining important safety and ethical concerns.